Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis)

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the safety of sodium phenylbutyrate (NaPB) treatment in subjects with amyotrophic lateral sclerosis (ALS) and the ability to take this medication without major side effects.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: US Department of Veterans Affairs; VA Office of Research and Development
• Collaborator: Muscular Dystrophy Association
• Treatments: 4-phenylbutyric acid

Criteria

Inclusion Criteria:

• Diagnosed with ALS

• At least 18 years of age

• Women, who can become pregnant, must actively use effective birth control measures

Exclusion Criteria:

• Must not have any other neurological (nervous system) disease

Veterans only are eligible to participate at VA sites.